Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The deal marks 10-year-old Moderna’s first acquisition. The company develops mRNA therapeutics and vaccines, and the move will enable it to utilise the synthetic biology and enzyme tech of 2018 ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S ...

Moderna provides updates on its business and ... three regulatory filings seeking the FDA’s approval. Intellia Therapeutics announced its strategic priorities and key anticipated milestones ...

Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of therapeutics in clinical trials that could be the ...